Riskpilot← Back to searchSign inGet full accessTCM Pharma ApS
APSBankruptCVR 39022508Hestbækvej 93Manufacture of pharmaceutical preparations · NACE 2120Est. 20171 employees
Revenue 2023
DKK 223K
+41% vs 2022
EBITDA margin
88.5%
+203% vs 2022
Equity ratio
10.6%
Financial strength
Net profit 2023
DKK 136K
+183% vs 2022
| Revenue | DKK 223K | +41% |
| EBITDA | DKK 198K | +203% |
| Net profit | DKK 136K | +183% |
| Total assets | DKK 503K | -47% |
| Equity | DKK 53K | +119% |
| Employees | 1 | — |
Legal name
TCM Pharma ApS
CVR number
39022508
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
18. oktober 2017
Share capital
DKK 52.083
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at forestå farmaceutisk forarbejdning, herunder eje og udleje bygning og materiel til brug herfor.
Address
Hestbækvej 93
Phone
+4540411544
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | -11 | -17 | 67 | 458 | 159 | 223 |
| Staff expenses | -0 | -0 | -0 | -0 | -94 | -0 |
| EBITDA | -11 | -54 | 66 | 458 | 65 | 198 |
| Depreciation & amort. | -0 | -68 | -278 | -283 | -165 | -23 |
| EBIT | -11 | -123 | -212 | 175 | -99 | 175 |
| Net financials | 2 | -13 | -41 | -41 | -65 | -38 |
| Profit before tax | -9 | -135 | -253 | 134 | -165 | 137 |
| Tax | -1 | -21 | 23 | -0 | -1 | 0 |
| Net profit | -8 | -114 | -276 | 134 | -163 | 136 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Total assets | 47 | 1.344 | 1.082 | 1.285 | 943 | 503 |
| Equity | 42 | -72 | -348 | -214 | -283 | 53 |
| Long-term debt | 0 | 1.102 | 686 | 437 | 142 | 0 |
| Short-term debt | 5 | 314 | 744 | 1.063 | 1.084 | 450 |
| Total debt | 5 | 1.416 | 1.430 | 1.499 | 1.226 | 450 |
EBITDA margin
88.5%
This company
15.8%
Market median
+460% vs market
20182023
Equity ratio
10.6%
This company
38.2%
Market median
-72% vs market
20182023
Return on equity
255.6%
This company
18.4%
Market median
+1289% vs market
20182023
Net profit margin
61.1%
This company
8.1%
Market median
+654% vs market
20182023
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20182023
Debt / equity
8.43×
This company
0.62×
Market median
-1260% vs market
20182023
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2017-10-18 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CE Unofficial title | Unofficial title | 2025 | — | — |
LG Management | Management | 2017 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
A.T.L. Holding ApS | Company | 90.0% | 90.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
A.T.L. Holding ApS
TCM Pharma ApS Board members of TCM Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carsten Egebæk Kjeldsen | Unofficial title | 0 companies |
| Lars Goul Nielsen | Management | 0 companies |